• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Supernus Pharmaceuticals Inc.

    4/30/26 5:02:25 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email
    DEFA14A 1 tm261453d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

    Filed by the Registrant x 

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

    SUPERNUS PHARMACEUTICALS, INC.

    (Name of the Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.

       

    ¨Fee paid previously with preliminary materials.

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

     

     

      

     

     

    GRAPHIC

    www.edocumentview.com/SUPN Step 1: Go to www.investorvote.com/SUPN. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/SUPN or scan the QR code — login details are located in the shaded bar below. Votes submitted electronically must be received by 11:00 a.m., Eastern Time, on June 18, 2026. Stockholder Meeting Notice 04AEVA Important Notice Regarding the Availability of Proxy Materials for the Supernus Pharmaceuticals, Inc. Stockholder Meeting to be Held on June 18, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Letter to Stockholders, Proxy Statement and 2025 Annual Report are available on the Internet at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 8, 2026 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Supernus Pharmaceuticals, Inc. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/SUPN. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials Supernus Pharmaceuticals, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by June 8, 2026. The 2026 Annual Meeting of Stockholders of Supernus Pharmaceuticals, Inc. will be held on June 18, 2026 at 10:00 a.m. Eastern Time, virtually via the Internet at meetnow.global/MU94RGM. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed, FOR Proposals 2, 3, and 4: 1. to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: 01 - Frederick M. Hudson 02 - Charles W. Newhall, III 2. To approve, on a non-binding basis, the compensation paid to our named executive officers. 3. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. 4. To consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the plan. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Stockholder Meeting Notice

    Get the next $SUPN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    10/9/2025$65.00Neutral → Overweight
    Piper Sandler
    7/30/2025$42.00Neutral → Overweight
    Cantor Fitzgerald
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    SEC Filings

    View All

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    5/20/26 4:37:01 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Supernus Pharmaceuticals Inc.

    10-Q - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    5/5/26 4:15:14 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    5/5/26 4:09:54 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Supernus Pharmaceuticals to Participate in June Investor Conferences

    ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences: 2026 Jefferies Global Healthcare ConferenceDate:Fireside chat:Place:Webcast Link:Wednesday, June 3, 202610:30 a.m. ETMarriott Marquis, New York, NYHere  Goldman Sachs 47th Annual Global Healthcare ConferenceDate:Place:Monday, June 8, 2026Loews Miami Beach, Miami Beach, Fla.   Investors interested in arranging a meeting with the Company's management during these confere

    5/27/26 4:30:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

    ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV. Investors interested in arranging a meeting with company management during the conference should contact the Bank of America conference coordinator. A live audio webcast of the presentation can be

    5/6/26 5:00:52 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Announces First Quarter 2026 Financial Results

    Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.Regulatory submission to the FDA for second supplier for ONAPGO expected in third quarter 2026, with potential approval by mid-year 2027.The Company reiterates full year 2026 financial guidance. ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceutical

    5/5/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Supernus Pharma upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $65.00

    10/9/25 8:22:44 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $42.00

    7/30/25 7:19:36 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

    2/19/25 7:05:55 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Supernus Pharmaceuticals Inc.

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/18/26 5:18:35 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO Khattar Jack A. acquired 12,500 shares, disposed of 12,500 shares and sold $1,763,124 worth of shares (35,000 units at $50.37), increasing direct ownership by 1% to 1,241,144 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/16/26 4:08:19 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hudson Frederick M. sold $271,725 worth of shares (5,369 units at $50.61), decreasing direct ownership by 8% to 60,413 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/16/26 4:07:41 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Financials

    Live finance-specific insights

    View All

    Supernus Announces First Quarter 2026 Financial Results

    Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.Regulatory submission to the FDA for second supplier for ONAPGO expected in third quarter 2026, with potential approval by mid-year 2027.The Company reiterates full year 2026 financial guidance. ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceutical

    5/5/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

    ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET to discuss these results. Following management's prepared remarks and discussion of business results, the call will be open for questions. A live webcast will be acces

    4/22/26 4:15:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

    Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™. Cash, cash equivalents and current marketable securities were $308.7 million at December 31, 2025. New patient initiation for ONAPGO resumed in the first quarter of 2026. Full

    2/24/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro

    4/20/26 5:00:00 PM ET
    $ACOG
    $KALV
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

    Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

    10/16/23 5:34:21 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/14/24 5:14:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/1/24 4:35:56 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

    SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    10/31/24 11:55:00 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care